Prof. Lucy Ogbadu is the director-general of the National Biotechnology Development Agency (NABDA). In his interview with NKECHI ISAAC, she talks about the current state of agricultural biotechnology development in Nigeria.
How many confined field trials are currently going on in Nigeria?
We have four confined field trials presently going on in Nigeria. They are BT Cowpea in Ahmadu Bello University, Institute of Agricultural Research, Zaria; African Bio-fortified Sorghum going on at the Ahmadu Bello University, Institute of Agricultural Research; BT Cotton equally being handled by IAR, Zaria; Newest Rice being handled by the National Cereals Research Institute, Badeggi.
How are the crops doing, how will you access their performance?
They are doing very well, were impressed with their performance. The BT Cowpea and ABS are ahead of the other two in the sense that they started earlier in 2011 and they have progressed tremendously. They are already into multi-locational trials as well as on-farm trials, especially the BT Cowpea.
When are you looking at harvesting these crops?
We harvest them periodically because there is no staple crop that grows for this length of time from 2011. So, obviously weve been harvesting and collecting the data on them, so it is not the issue of when we harvest because none of them grows more than a period of four to five months. So, weve been harvesting and studying them further.
When are we looking at commercialising these crops, the target was previously 2018 but it has been shifted to 2019. Can the nation make this new timeline?
The BT Cowpea will most likely be the first to go out for commercialisation and it will not go beyond 2019 in the sense that we want to be doubly sure on all were doing with the crop. The scientists are happy with the results they are getting, the farmers working with the scientists are equally happy with the results theyre getting in terms of out-performing the conventional ones theyve been used to. So, hopefully by 2019 latest, it should be out in the market.
Are there any regulatory hurdles that remain before these crops can be successfully commercialised in Nigeria?
Looking from the perspective of the government in terms of policy, there are no hurdles because the establishment of this agency by the government shows the government is in support of biotechnology. Now in terms of regulation all the risk assessment, all stewardship in terms of its performance have all been carried out by our scientists that are handling the crops.
This is about the last stage of what they need to do before it is commercialised in the sense that the seeds need to be multiplied before we can say they are ready for release but of course other regulatory hurdle that may interest you is that of registration of the crop with our varietal release committee, a unit based at Ibadan which will require them to convene a meeting of the varietal release committee to look at all the descriptors that are required to be looked at before they are registered and adjudged ready for release. That is about the only hurdle that is left.
After commercialization, how accessible will this crop be to the local farmers at the grassroots who are supposed to be the main benefactors of this technology?
They wont be different from all other seeds in the sense that once they are considered okay for commercial release then it will be at the national centre for genetic resources and biotechnology in Ibadan and at that stage the only thing that will be left will be for multiplication. You know the PIs will handle the multiplication along with the extension workers after which they will be ready for uptake for farmers that are interested and other interested people.
Seed companies are sceptical about genetically modified seeds, theyre scared that multinational seed companies like Monsanto and the likes will take over their market once GM crops are produced?
The process were currently adopting shows that our scientists and farmers are involved. Now if it gets to the stage of uptake and our indigenous Nigerian seed companies refuse to come forward to take them for multiplication and release them they shouldnt blame other seed companies that come forward to multiply them. In this case our own seed companies will definitely participate in the multiplication and release. I am sure of that. They should be able to come forward and participate because the qualities of the seeds are attractive so they should be able to come forward and take them up.
No foreign seed company will jump over the laid down protocols to come and introduce any foreign seed to Nigeria, it is not possible because the regulatory framework is in place to ensure that does not happen.
Some school of thoughts believe we should channel efforts at reducing food wastage instead of applying biotechnology to boost agriculture and ensure food security. What is your take on this?
Agricultural biotechnology is not limited to GMO alone. In fact the same technology can be applied to crops in order to check the food wastage, prolong the shelf life of agricultural produce, it can be applied to crops to ensure that improved yield of crops. So, there are various ways this technology can be used advantageously on crops. It can also be used to improve the nutritional quality of the crops. So, it is not limited to GM and as a matter of fact GM is only a technique that can give us so many other advantages. This is why we feel the public should trust our scientists enough to leave the matter to them because it is a complex scientific process that people who do not really understand science cant understand. The same technology can be used to improve the shelf life of tomato for instance such that it can stay on the shelf for much longer period without spoiling.
We cannot make any serious progress in agriculture without applying biotechnology; were talking about using agriculture to diversify Nigerias economy, if that is so how else other than mechanisation. In addition to mechanisation you must have quality seeds, deploy technology in order to use agriculture to diversify the economy. It is not with our crude system of agriculture that we can use it to diversify the economy. What this simply means is that were losing a lot if we do not use advanced technology, which is agricultural biotechnology to diversify the economy.
Through advanced agricultural biotechnology we can revolutionise agriculture and ensure food security using agricultural biotechnology. To downplay on it means the nation is losing heavily and invariably unserious about diversifying the economy through agriculture. Theres no other way, it is through agricultural biotechnology that we can inject and revolutionise agriculture to diversify Nigerias economy.
Follow this link:
We Can't Diversify Economy Through Agriculture Without Biotechnology Ogbadu - Leadership Newspapers
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022